Our analysis of different TNF-α antagonist drugs did not reveal significant associations with TB risk for specific drugs, but it underscores the importance of considering the overall risk-benefit profile when selecting a TNF-α antagonist for a particular patient. The gene discussed is TNF; the disease is tuberculosis.